Drug fools immune system to fight allergy

Sep 29, 2006

A Swiss company is testing a hay fever drug that tricks the human immune system into acting as if it has been exposed to an infectious agent found in dirt.

Cytos Biotechnology has tested CYT 003-QbG10 on 10 people with hay fever and has found that their sensitivity to grass pollen is 1 percent after treatment to what it was before, New Scientist magazine reports. So far, the subjects have been free of hay fever for eight months.

A previous study found that people who are sensitive to dust mites have remained free of symptoms for at least a year.

The drug mimics the effect of exposure to mycobacteria, which somehow reboots the immune system, New Scientist said.

Copyright 2006 by United Press International

Explore further: Determine patient preferences by means of conjoint analysis

add to favorites email to friend print save as pdf

Related Stories

Tropical Storm Genevieve forms in Eastern Pacific

50 minutes ago

The seventh tropical depression of the Eastern Pacific Ocean formed and quickly ramped up to a tropical storm named "Genevieve." NOAA's GOES-West satellite captured an infrared image of the newborn storm ...

Recommended for you

Determine patient preferences by means of conjoint analysis

22 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0